胰腺炎与胰腺导管腺癌:关联与鉴别
本文阐述肿块型慢性胰腺炎(MFCP)与胰腺导管腺癌(PDAC)的鉴别诊断困境,指出两者预后与处理差异显著但多种影像表现重叠;灌注CT或动态增强MRI可显示不同强化模式,MRCP上胰管穿通征更常见于MFCP,而主胰管截断伴上游扩张及双管征更常见于PDAC;组织取样仍是鉴别最可靠且目前处理通常必需的方法。
要点
- MRCP上胰管穿通征更常见于MFCP,主胰管截断伴上游扩张及双管征更常见于PDAC。
- 灌注CT或DCE-MRI上MFCP与PDAC可能显示不同强化模式,有助于鉴别。
- 组织取样是鉴别两者最可靠的方法,目前处理通常必需。
核心结论
- MFCP与PDAC的影像表现显著重叠,但部分影像特征可能提示某一诊断多于另一诊断。
- 组织取样是鉴别MFCP与PDAC最可靠的方法,目前处理通常必需。
研究设计与样本
- 本文为综述,原文未报告检索范围与纳入文献数量。
关键影像表现/征象
- MRCP上胰管穿通征更常见于MFCP。
- 主胰管截断伴上游扩张更常见于PDAC。
- 双管征(胆总管与胰管同时梗阻/截断)更常见于PDAC。
- MFCP与PDAC在灌注CT和/或DCE-MRI上可能显示不同强化模式。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准。
临床应用与阅片要点
- 阅片时注意MRCP上胰管穿通征提示MFCP,主胰管截断伴上游扩张及双管征提示PDAC。
- 灌注CT或DCE-MRI的强化模式可能有助于鉴别MFCP与PDAC。
- 组织取样是鉴别两者最可靠的方法,目前处理通常必需。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The discrimination of mass-forming chronic pancreatitis (MFCP) from pancreatic ductal adenocarcinoma (PDAC) is a central diagnostic dilemma. It is important to differentiate these entities since they have markedly different prognoses and management. Importantly, the appearance of these two entities significantly overlaps on a variety of imaging modalities. However, there are imaging features that may be suggestive of one entity more than the other. MFCP and PDAC may show different enhancement patterns on perfusion computed tomography (CT) and/or dynamic contrast-enhanced MRI (DCE-MRI). The duct-penetrating sign on magnetic resonance cholangiopancreatography (MRCP) is more often associated with MFCP, whereas abrupt cutoff with upstream dilatation of the main pancreatic duct and the double-duct sign (obstruction/cutoff of both the common bile duct and pancreatic duct) are more often associated with PDAC. Nevertheless, tissue sampling is the most reliable method to differentiate between these entities and is currently generally necessary for management.
引用
- Elsherif SB, Virarkar M, Javadi S, et al. Pancreatitis and PDAC: association and differentiation. Abdom Radiol (NY). 2020. PMID: 31705251. doi:10.1007/s00261-019-02292-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。